Abstract:Objective To explore the predictive value of combined detection of serum suppressor of cytokine signal 1 (SOCS1), matrix metalloproteinase-9 (MMP-9), squamous cell carcinoma antigen (SCCA), and thymidine kinase 1 (TK1) for clinical efficacy in cervical cancer patients undergoing concurrent chemoradiotherapy. Methods A total of 60 cervical cancer patients who were treated with concurrent chemoradiotherapy for 3 months at Anhui Zhongke Gengjiu Hospital from February 2022 to February 2023 were selected. According to the therapeutic efficacy, the 60 patients were divided into an effective group and an ineffective group. The serum levels of SOCS1, MMP-9, SCCA, and TK1 before treatment were measured in both groups. Univariate and multivariate logistic regression were used to analyze the relationship between these biomarkers and the efficacy of concurrent chemoradiotherapy in cervical cancer patients. Receiver operating characteristic (ROC) curves were drawn to assess the predictive value of individual and combined detection of serum SOCS1, MMP - 9, SCCA, and TK1 for evaluating the therapeutic efficacy of concurrent chemoradiotherapy. Results Among the 60 patients, 35 (58.33%) were in the effective group and 25 (41.67%) in the ineffective group. Univariate analysis showed a statistically significant difference in Federation International of Gynecology and Obstetrics (FIGO) staging between the effective and ineffective groups (Z= 2.649, P= 0.008). The proportion of tumors with a diameter of<5 cm was higher in the effective group than in the ineffective group, with a statistically significant difference (85.71% vs 60.00%, χ²=5.143, P= 0.023). Compared to the ineffective group, the serum levels of MMP-9 (t= 2.481, P= 0.016), SCCA (t= 2.719, P= 0.009), and TK1 (t= 2.850, P= 0.006) were lower, while SOCS1 levels were higher (t= 2.581, P= 0.012) in the effective group, with statistically significant differences. Multivariate logistic regression analysis showed that serum SOCS1, MMP-9, SCCA, and TK1 levels were independent factors affecting the efficacy of concurrent chemoradiotherapy (P＜0.05). The areas under the ROC curves (AUC) for serum SOCS1, MMP-9, SCCA, and TK1 in predicting the efficacy of concurrent chemoradiotherapy were 0.725, 0.704, 0.755, and 0.671, respectively. The combined AUC for the four biomarkers was 0.822, demonstrating higher predictive efficacy than single detections. Conclusion Serum levels of SOCS1, MMP-9, SCCA, and TK1 are important factors influencing the efficacy of concurrent chemoradiotherapy in cervical cancer patients, and the combined prediction using these four markers has high value.